General Information
The combination of valsartan and sacubitril constitutes a novel strategy to reduce the risk of death and hospitalization due to heart failure. It is used in patients with chronic heart failure and reduced ejection fraction for almost all severity levels of heart failure (except for the lowest, level I, by New York Heart Association Functional Classification). Ejection fraction is a measurement for assessing the heart’s ability to pump out blood and for diagnosing and monitoring heart failure.
About the API
Systematic name
Octadecasodiumhexakis(4-{[(1S,3R)-1-([1,1´-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)hexakis(N-pentanoyl-N-{[2´-(1H-tetrazol-1-id-5-yl)[1,1´-biphenyl]-4-yl]methyl}-L-valinate)—water (1/15).
Trade name(s)
Entresto, LCZ696
Technology
Synthetic
Molecular Formula
C48H55N6O8Na3 2.5 H2O
Molecular Weight
957.99 g/mol
Physical properties
White to almost white crystalline powder
Therapeutic category
Cardiovascular
Available formulations
Oral Solid
Regulations
US DMF
US DMF